Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eikon Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eikon Therapeutics's regulatory disclosures and financial reporting.
Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share. The award vests in equal monthly installments over 48 months, subject to his continued service.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics, Inc. reported that director Robert Luther Huffines received a grant of stock options covering 25,873 shares of the company’s stock. These options were awarded as a form of compensation and will vest in equal monthly installments over 48 months, as long as he continues in service during that period.
FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.
PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.
Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.
Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.
Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.
The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.
Eikon Therapeutics ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares of common stock, representing 5.2% of the class. The filing cites a shares outstanding base of 53,984,337 after giving effect to the offering described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.
Platinum Falcon B 2018 RSC Limited is reported as the direct owner of 1,147,138 shares (shown as 2.1% of the class); Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority and certain voting/dispositive powers are shared between them.
The Column Group investment entities and principals have disclosed a large ownership position in Eikon Therapeutics, Inc. common stock. Together, they report beneficial ownership of 6,353,712 shares, representing 11.6% of Eikon’s outstanding common stock.
The stake is held through multiple venture funds and includes shares underlying warrants exercisable within 60 days. The position stems from preferred stock investments made between 2019 and 2025 that converted into common stock at Eikon’s initial public offering, plus additional common shares purchased in the IPO at $18 per share.
The investors describe their holdings as for general investment purposes and may increase or decrease their position over time. They also hold registration rights under an investors’ rights agreement and have agreed to 180-day lock-up restrictions following the IPO underwriting agreement.
Eikon Therapeutics, Inc. received a Schedule 13G filing from a group of Foresite Capital investment funds and their affiliated managers, disclosing a significant passive ownership stake in its common stock. The filing reports that various Foresite Capital funds and entities collectively attribute beneficial ownership to James B. Tananbaum of 4,148,519 shares, representing 7.7% of the common stock, based on 53,984,337 shares outstanding as of February 4, 2026.
Individual Foresite vehicles report smaller positions, including Foresite Capital Fund IV, L.P. with 1,960,774 shares (3.6%), Foresite Capital Fund V, L.P. with 1,353,168 shares (2.5%), Foresite Capital Opportunity Fund V, L.P. with 425,852 shares (0.8%), and Foresite Capital VI-A, LLC with 408,725 shares (0.8%). Each entity reports sole voting and dispositive power over its shares, with those powers ultimately attributable to Tananbaum through the general partner and managing member structures.
The Reporting Persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Eikon Therapeutics, indicating a passive investment posture consistent with a Schedule 13G filing.